Key Points
-
Amazon’s earnings are expected to continue robust growth.
-
BeOne Medicines awaits U.S. approval for a new treatment after receiving Chinese regulatory clearance.
-
Enterprise Products Partners offers a 6.6% forward distribution yield, having increased distributions for 27 consecutive years.
Amazon (NASDAQ: AMZN) is projected to report robust earnings growth this week, despite having lagged the S&P 500 over the past 12 months. The company’s bottom line is benefiting from efficiency initiatives and increasing returns from its Amazon Web Services (AWS) segment, which is expected to gain further traction in 2026 due to expanding investments in artificial intelligence (AI).
BeOne Medicines (NASDAQ: ONC) recently received Chinese regulatory approval for its drug sonrotoclax, aimed at treating relapsed/refractory blood cancers, and is awaiting U.S. approval. Meanwhile, Enterprise Products Partners (NYSE: EPD) is attracting attention from income investors with a 6.6% distribution yield and a track record of 27 consecutive years of distribution increases, driven by rising demand for natural gas due to AI data center construction.
